Evidence map›Paper›PMID 39280607›Full record

ArticleiScience2024

Knowledge graphs facilitate prediction of drug response for acute myeloid leukemia.

Guangrong Qin, Yue Zhang, Jeffrey W Tyner, Christopher J Kemp, Ilya Shmulevich

Abstract read
In one paragraph

Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Guangrong QinInstitute for Systems Biology, Seattle, WA 98109, USA.
Yue ZhangInstitute for Systems Biology, Seattle, WA 98109, USA.
Jeffrey W TynerKnight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.
Christopher J KempFred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Ilya ShmulevichInstitute for Systems Biology, Seattle, WA 98109, USA.

Funding

A Patient-Centric Approach to Advance Functional Precision OncologyU01CA282109 · NCI · FRED HUTCHINSON CANCER CENTER · PI CHRISTOPHER J KEMP · 2023 to 2026
$4.2M
Prototype System for AML Digital TwinsR01CA270210 · NCI · INSTITUTE FOR SYSTEMS BIOLOGY · PI VESTEINN THORSSON · 2023 to 2026
$2.8M
NCI NIH HHS R01 CA270210NCI NIH HHS U01 CA282109
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is a highly aggressive and heterogeneous disease, underscoring the need for improved therapeutic options and methods to optimally predict responses. With the wealth of available data resources, including clinical features, multiomics analysis, and

Indexed as

BioinformaticsBiological sciencesCancer

Identifiers

PMID39280607
PMCPMC11401200

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.